{"filing":{"accession_number":"0001609550-26-000045","cik":"0001609550","ticker":"INSP","company_name":"Inspire Medical Systems, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"insp-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000045/insp-20260803.htm"},"events":[{"id":23428,"run_id":21181,"accession_number":"0001609550-26-000045","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Inspire Medical Systems disclosed Q2 2026 financial results (quarter ended June 30, 2026) with revenue of $200.6 million, diluted EPS of $0.01, and adjusted diluted EPS of $0.14, along with raised full-year 2026 guidance and a strategic growth plan (Project Horizon). The earnings announcement was furnished as a press release exhibit accompanying both Item 2.02 and Item 7.01 disclosures.","company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23647,"accession_number":"0001609550-26-000045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly revenue ($200.6 million), diluted EPS ($0.01), adjusted diluted EPS ($0.14), operating cash flow ($23.2 million), and raised full-year 2026 guidance. This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:31:07.636033+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23648,"accession_number":"0001609550-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references presentation materials for investor meetings, but the substantive content furnished as Exhibit 99.1 is a press release announcing second quarter 2026 financial results (revenue of $200.6 million, diluted EPS of $0.01, adjusted diluted EPS of $0.14), raised full-year 2026 guidance, and a strategic growth plan (Project Horizon). This is a classic earnings release disclosure, material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:31:07.636033+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23647,"accession_number":"0001609550-26-000045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly revenue ($200.6 million), diluted EPS ($0.01), adjusted diluted EPS ($0.14), operating cash flow ($23.2 million), and raised full-year 2026 guidance. This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:31:07.636033+00:00","company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","filing_date":"2026-08-03"},{"id":23648,"accession_number":"0001609550-26-000045","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references presentation materials for investor meetings, but the substantive content furnished as Exhibit 99.1 is a press release announcing second quarter 2026 financial results (revenue of $200.6 million, diluted EPS of $0.01, adjusted diluted EPS of $0.14), raised full-year 2026 guidance, and a strategic growth plan (Project Horizon). This is a classic earnings release disclosure, material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:31:07.636033+00:00","company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","filing_date":"2026-08-03"}]}